TIDMCREO

RNS Number : 8288Y

Creo Medical Group PLC

13 May 2019

Creo Medical Group plc

("Creo" or "the Company")

Posting of Annual Reports and Accounts

Notice of Annual General Meeting

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that its Report and Accounts for the 18 month period ended 31 December 2018, together with its Notice of Annual General Meeting ("AGM") and a Form of Proxy, will be mailed out to shareholders today.

These documents are available on the Company's website:

http://investors.creomedical.com/investors/reports-and-presentations/2019

The AGM will be held at 10 a.m. on Thursday 6 June 2019 at the Company's registered office, Creo House, Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Wales NP16 5UH.

 
 Creo Medical Group plc 
 Richard Rees (CFO)                                                    +44 (0)129 160 6005 
 
 Cenkos Securities                                                     +44 (0)20 7397 8900 
 Stephen Keys / Mark Connelly (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus                                                     Mob: +44 (0)7980 541 893 
 Helen Cresswell                                                  Mob: +44 (0)7841 917 679

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radio frequency energy (for precise localised cutting) and microwave energy (for controlled coagulation). This technology provides clinicians with flexible, accurate and controlled surgical solutions.

Creo's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which Creo has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. Creo intends to further develop the CROMA Advanced Energy platform for use on flexible and rigid endoscopic platforms for precise resection, dissection, haemostasis and ablation. Creo believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEANSDFLXNEEF

(END) Dow Jones Newswires

May 13, 2019 05:50 ET (09:50 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Creo Medical Charts.